RougeTx raised $58 million in a Series A to advance an oral small-molecule therapy candidate for hereditary hemorrhagic telangiectasia (HHT). The company’s approach centers on reattaching pericytes to stabilize vessels, shifting beyond purely symptomatic management toward a disease-mechanism strategy. The funding provides runway for translation into clinical testing, with a stated goal of moving a potential once-daily oral option closer to patients. The deal also signals continued investor interest in oral approaches for vascular rare diseases, where earlier-stage entrants can gain differentiation through mechanism and convenience.